1. Home
  2. ERII vs PRTA Comparison

ERII vs PRTA Comparison

Compare ERII & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Energy Recovery Inc.

ERII

Energy Recovery Inc.

HOLD

Current Price

$8.11

Market Cap

595.9M

Sector

Technology

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.19

Market Cap

526.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ERII
PRTA
Founded
1992
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
595.9M
526.7M
IPO Year
2008
2013

Fundamental Metrics

Financial Performance
Metric
ERII
PRTA
Price
$8.11
$10.19
Analyst Decision
Buy
Buy
Analyst Count
3
9
Target Price
$17.07
$19.00
AVG Volume (30 Days)
1.3M
486.4K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
5.00
N/A
EPS
N/A
0.60
Revenue
$134,987,000.00
$814,000.00
Revenue This Year
N/A
$1,111.38
Revenue Next Year
$20.55
N/A
P/E Ratio
N/A
$16.63
Revenue Growth
N/A
N/A
52 Week Low
$8.14
$4.53
52 Week High
$18.31
$11.80

Technical Indicators

Market Signals
Indicator
ERII
PRTA
Relative Strength Index (RSI) 33.47 52.24
Support Level N/A $9.81
Resistance Level $11.58 $10.55
Average True Range (ATR) 0.42 0.53
MACD -0.02 0.03
Stochastic Oscillator 1.61 62.90

Price Performance

Historical Comparison
ERII
PRTA

About ERII Energy Recovery Inc.

Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: